Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder

다국어 초록 (Multilingual Abstract)

Considerable progress has been made in treatments for multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) over the last several decades. However, the present treatments do not show satisfactory efficacy or safety in a considerable proportion of patients, who experience relapse or disability progression despite receiving treatment and suffer from side effects, which can be severe. Improvements in the understanding of the pathophysiologies of MS and NMOSD have led to numerous therapeutic approaches being proposed and developed. Monoclonal antibodies (mAbs) are receiving increasing attention because of their specificity of action and likelihood of high efficacy with fewer side effects.
Many mAbs have been evaluated, and some have been approved for MS or NMOSD treatment.
This article reviews the use of mAbs for treating MS and NMOSD, including summarizing their mechanisms of action, efficacy, and safety profiles.

참고문헌 (Reference)

1 Cree BAC, "Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial" 394 : 1352-1363, 2019

2 Kim SH, "Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab" 72 : 989-995, 2015

3 Nussenblatt RB, "Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb : a phase I/II clinical trial" 96 : 7462-7466, 1999

4 Sato D, "Treatment of neuromyelitis optica: an evidence based review" 70 : 59-66, 2012

5 Jacob A, "Treatment of neuromyelitis optica with rituximab : retrospective analysis of 25 patients" 65 : 1443-1448, 2008

6 Lauenstein AS, "Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab" 2014 : 2014

7 Waldmann TA, "Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2" 72 : 1805-1816, 1988

8 Teeling JL, "The biological activity of human CD20monoclonal antibodies is linked to unique epitopes on CD20" 177 : 362-371, 2006

9 Bar-Or A, "Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis : the MIRROR study" 90 : e1805-e1814, 2018

10 Stork L, "Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis" 25 : 1618-1632, 2019

11 Giovannoni G, "Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis : an integrated analysis of clinical studies" 9 : 36-46, 2016

12 Agius MA, "Safety and tolerability of inebilizumab (MEDI551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study" 25 : 235-245, 2019

13 Cadavid D, "Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebocontrolled, phase 2 trial" 18 : 845-856, 2019

14 Cadavid D, "Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial" 16 : 189-199, 2017

15 Sorensen PS, "Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis : a phase 2 study" 82 : 573-581, 2014

16 Gold R, "Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study" 16 : 117-, 2016

17 Marcinnò A, "Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders" 5 : e498-, 2018

18 Clifford DB, "Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis" 68 : 1156-1164, 2011

19 Evens AM, "Rituximab-associated hepatitis B virus(HBV)reactivation in lymphoproliferative diseases : meta-analysis and examination of FDA safety reports" 22 : 1170-1180, 2011

20 Alping P, "Rituximab versus fingolimod after natalizumab in multiple sclerosis patients" 79 : 950-958, 2016

21 Hawker K, "Rituximab in patients with primary progressive multiple sclerosis : results of a randomized double-blind placebo-controlled multicenter trial" 66 : 460-471, 2009

22 Salzer J, "Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy" 87 : 2074-2081, 2016

23 Naismith RT, "Rituximab add-on therapy for breakthrough relapsing multiple sclerosis : a 52-week phase II trial" 74 : 1860-1867, 2010

24 Ho PR, "Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies" 16 : 925-933, 2017

25 Bumgardner GL, "Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplan-tation" 72 : 839-845, 2001

26 Kim SH, "Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years" 68 : 1412-1420, 2011

27 Ciron J, "Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders" 174 : 255-264, 2018

28 Wootla B, "Recent advances in monoclonal antibody therapies for multiple sclerosis" 16 : 827-839, 2016

29 D’Arena G, "Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders" 64 : 275-281, 2000

30 Molloy ES, "Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?" 8 : 144-146, 2008

31 Kalisch A, "Progressive multifocal leukoencephalopathy in patients with a hematological malignancy : review of therapeutic options" 60 : 47-53, 2014

32 Isidoro L, "Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab" 2014

33 Langer-Gould A, "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab" 353 : 375-381, 2005

34 Waggoner J, "Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant" 28 : 395-398, 2009

35 Kleinschmidt-DeMasters BK, "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis" 353 : 369-374, 2005

36 Van Assche G, "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease" 353 : 362-368, 2005

37 Yednock TA, "Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin" 356 : 63-66, 1992

38 Collongues N, "Pharmacotherapy for neuromyelitis optica spectrum disorders : current management and future options" 79 : 125-142, 2019

39 Major EO, "Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned" 17 : 467-480, 2018

40 김우준, "Oral Disease-Modifying Therapies for Multiple Sclerosis" 대한신경과학회 11 (11): 9-19, 2015

41 Barkhof F, "Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis" 93 : e1778-e1786, 2019

42 Montalban X, "Ocrelizumab versus placebo in primary progressive multiple sclerosis" 376 : 209-220, 2017

43 Hauser SL, "Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis" 376 : 221-234, 2017

44 Kappos L, "Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled, multicentre trial" 378 : 1779-1787, 2011

45 김우준, "New Insights into Neuromyelitis Optica" 대한신경과학회 7 (7): 115-127, 2011

46 Ambrose LR, "Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab" 114 : 3052-3055, 2009

47 Rudick RA, "Natalizumab plus interferon beta-1a for relapsing multiple sclerosis" 354 : 911-923, 2006

48 Clerico M, "Natalizumab in multiple sclerosis : long-term management" 18 : 940-, 2017

49 Iwasa T, "Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis" 43 : 70-72, 2011

50 Voge NV, "Monoclonal antibodies in multiple sclerosis : present and future" 7 : 20-, 2019

51 Arango Duque G, "Macrophage cytokines : involvement in immunity and infectious diseases" 5 : 491-, 2014

52 Beauchemin P, "MS arising during tocilizumab therapy for rheumatoid arthritis" 22 : 254-256, 2016

53 Gout T, "Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab : a systematic literature review" 30 : 1471-1474, 2011

54 Ringelstein M, "Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder" 72 : 756-763, 2015

55 Clerico M, "Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis" 16 : 963-972, 2017

56 O’Connor P, "Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study" 83 : 78-86, 2014

57 Sangalli F, "Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients" 3 : 520-526, 2014

58 Mi S, "LINGO-1 negatively regulates myelination by oligodendrocytes" 8 : 745-751, 2005

59 Mi S, "LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex" 7 : 221-228, 2004

60 Vincenti F, "Interleukin2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation" 338 : 161-165, 1998

61 Uzawa A, "Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders : a special focus on neuromyelitis optica" 469 : 144-149, 2017

62 Ayzenberg I, "Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy" 70 : 394-397, 2013

63 Harmel J, "Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab" 14 : 247-, 2014

64 Thomas TC, "Inhibition of complement activity by humanized antiC5 antibody and single-chain Fv" 33 : 1389-1401, 1996

65 Nishimoto N, "Inhibition of IL-6 for the treatment of inflammatory diseases" 4 : 386-391, 2004

66 Malucchi S, "High-risk PML patients switching from natalizumab to alemtuzumab : an observational study" 6 : 145-152, 2017

67 Smalls DJ, "Hepatitis B virus reactivation : risk factors and current management strategies" 39 : 1190-1203, 2019

68 Goodman AD, "GLANCE : results of a phase 2, randomized, double-blind, placebo-controlled study" 72 : 806-812, 2009

69 Hale G, "From laboratory to clinic : the story of CAM PA TH-1" 40 : 243-266, 2000

70 Fox E, "Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)" European Committee for Treatment and Research in Multiple Sclerosis 2019

71 Dmytrijuk A, "FDA report : eculizumab(Soliris)for the treatment of patients with paroxysmal nocturnal hemoglobinuria" 13 : 993-1000, 2008

72 U.S. Food & Drug Administration, "FDA approves new drug to treat multiple sclerosis" U.S. Food & Drug Administration

73 Bleeker WK, "Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody" 140 : 303-312, 2008

74 Akaishi T, "Efficiency of antibody therapy in demyelinating diseases" 29 : 327-335, 2017

75 Araki M, "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica : a pilot study" 82 : 1302-1306, 2014

76 Burmester GR, "Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)" 75 : 68-74, 2016

77 Damato V, "Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders : a systematic review and meta-analysis" 73 : 1342-1348, 2016

78 Hu Y, "Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis : a systematic review and meta-analysis" 18 : 542-548, 2019

79 Butzkueven H, "Efficacy and safety of natalizumab in multiple sclerosis : interim observational programme results" 85 : 1190-1197, 2014

80 Biogen, "Efficacy and safety of BIIB033 (opicinumab) as an add-on therapy to disease-modifying therapies (DMTs) in relapsing multiple sclerosis (MS) (AFFINITY)" U.S. National Library of Medicine

81 Traboulsee A, "Efficacy and Safety of Satralizumab Monotherapy for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder (NMOSD):Results from SAkuraStar, a Double-blind, Placebo-controlled, Phase 3Clinical Study" 2019

82 Gao F, "Effectiveness of rituximab in neuromyelitis optica : a meta-analysis" 19 : 36-, 2019

83 Kapoor R, "Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, doubleblind, placebo-controlled trial with an open-label extension" 17 : 405-415, 2018

84 Pittock SJ, "Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder" 381 : 614-625, 2019

85 Pittock SJ, "Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders : an open-label pilot study" 12 : 554-562, 2013

86 European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection" 67 : 370-398, 2017

87 Kieseier BC, "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica : implication for cellular immune responses" 70 : 390-393, 2013

88 O’Connor PW, "Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis" 76 : 1858-1865, 2011

89 Cooper LJN, "Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies" 33 : 83-89, 2004

90 Cohan SL, "Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis" 7 : E18-, 2019

91 Bianchi A, "Daclizumab-induced encephalitis in multiple sclerosis" 25 : 1557-1559, 2019

92 Wynn D, "Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta" 9 : 381-390, 2010

93 Giovannoni G, "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, doubleblind extension trial" 13 : 472-481, 2014

94 Gold R, "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebocontrolled trial" 381 : 2167-2175, 2013

95 Kappos L, "Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis" 373 : 1418-1428, 2015

96 Baldassari LE, "Daclizumab : development, clinical trials, and practical aspects of use in multiple sclerosis" 14 : 842-858, 2017

97 Berger JR, "Considerations on discontinuing natalizumab for the treatment of multiple sclerosis" 68 : 409-411, 2010

98 Jeong IH, "Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints" 22 : 329-339, 2016

99 Hauser SL, "B-cell depletion with rituximab in relapsing-remitting multiple sclerosis" 358 : 676-688, 2008

100 Le Garff-Tavernier M, "Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion" 28 : 230-233, 2014

101 Jarius S, "Antibody to aquaporin-4 in the long-term course of neuromyelitis optica" 131 : 3072-3080, 2008

102 Igawa T, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization" 28 : 1203-1207, 2010

103 Plavina T, "Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy" 76 : 802-812, 2014

104 Cree BAC, "An open label study of the effects of rituximab in neuromyelitis optica" 64 : 1270-1272, 2005

105 CAMMS223 Trial Investigators, "Alemtuzumab vs. interferon beta-1a in early multiple sclerosis" 359 : 1786-1801, 2008

106 Cohen JA, "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial" 380 : 1819-1828, 2012

107 Azzopardi L, "Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series" 263 : 25-29, 2016

108 McCall B, "Alemtuzumab to be restricted pending review, says EMA" 393 : 1683-, 2019

109 Havrdova E, "Alemtuzumab in the treatment of multiple sclerosis : key clinical trial results and considerations for use" 8 : 31-45, 2015

110 Evan JR, "Alemtuzumab for the treatment of multiple sclerosis" 18 : 323-334, 2018

111 Coles AJ, "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3trial" 380 : 1829-1839, 2012

112 Federle L, "Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following natalizumab break : clinical case and literature review" 30 : 262-264, 2019

113 Garnock-Jones KP, "Alemtuzumab : a review of its use in patients with relapsing multiple sclerosis" 74 : 489-504, 2014

114 Sellner J, "A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis" 18 : 255-261, 2019

115 Polman CH, "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis" 354 : 899-910, 2006

116 Mealy MA, "A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder" 98 : e15944-, 2019

117 de Seze J, "A Double-blind Placebo-controlled Study of Satralizumab (SA237), a Recycling Anti-IL-6 Receptor Monoclonal Antibody, as Add-on Therapy for Neuromyelitis Optica Spectrum Disorder (NMOSD)" 2018